All In Biotech

Drug Trial Radar · NCT04118114

Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors

An Open Label Phase II Study of the Efficacy and Tolerability of PRL3-ZUMAB and Predictive Biomarkers in Advanced Solid Tumours

Last checked: Nov 20, 2026Latest source record: May 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Sep 3, 2019

Primary completion

Oct 17, 2025

Study completion Oct 17, 2025

Sponsor

Lead sponsor
National Cancer Centre, SingaporeAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
INTRA-IMMUSG PRIVATE LIMITED
First posted
Oct 8, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 21 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase II, open-label, single dose level study of PRL3-ZUMAB monotherapy in patients with advanced solid tumours that have failed standard therapy. Approximately 30 patients will be recruited with \~10 gastric cancers and \~10 hepatocellular carcinomas. Patients who have received at least 1 dose of PRL3-ZUMAB will be evaluable for toxicity and efficacy. PRL3-ZUMAB will be given IV every 2 weeks for up to 12 infusions in the absence of unmanageable toxicities or disease progression. Patients who are benefitting from the treatment may continue on PRL3-ZUMAB beyond 12 infusions with the agreement of the study drug provider. PRL3-ZUMAB at the RP2D in tumour types enriched for known PRL-3 expression for efficacy and tolerability will be evaluated. There will also be in depth molecular profiling of tissues in patients who have an objective response or prolonged disease stabilization to identify predictive/selection biomarkers as well as evaluation of the oncogenic signaling modulation and immunomodulation by PRL3-ZUMAB and its potential for future combination with other targeted therapies or immunotherapy.

Conditions

  • Gastric Cancer
  • Hepatocellular Carcinoma
  • Advanced Solid Tumor

Interventions

  • PRL3-zumabDrug

    IV administration every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: From start of treatment to first occurence of disease progression or death, up to 2 years
  2. Number of patients that do not have disease progression at 16 weeks from start of treatmentTime frame: 16 weeks after start of treatment
  3. Treatment related adverse events rateTime frame: From start of treatment to 30 days after last dose of study drug

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • National Cancer Center Singapore

    Singapore, Singapore

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.